Area Poster - Oral Poster

Antiretroviral Therapy I

OP 1

Real-life Experience with Dolutegravir-Based Two-Drug Regimens

R. Pincino

OP 2

Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine or Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors in a single center in Italy

F. Lagi

 
 
OP 3

Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study)

S. Cicalini

 
 
OP 4

Efficacy and tolerability of a switch to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed PLWH

D. Canetti

OP 5

Efficacy, safety and feasibility of a rapid antiretroviral therapy starting B/F/TAF in advanced hiv disease (Rainbow study)

M. Camici

 
 
OP 6

Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH) in routine clinical practice: 6-month results of the Italian BICSTaR cohort

A. d'Arminio Monforte

 
 

Antiretroviral Therapy II

OP 43

Changes in serum inflammatory and immune activation markers associated with lamivudine/dolutegravir and tenofovir alafenamide/emtricitabine/bictegravir as initial antiretroviral treatment

L. Calza

 
 
OP 44

Cardiovascular risk and lipid profile after switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi in people living with HIV and controlled plasma viremia

S. Rusconi

OP 45

Who could be eligible for long-acting antiretroviral treatment? A snapchat from Antiviral Response Cohort Analysis (ARCA) Italian cohort

A. De Vito

 
 
OP 46

HIV-DNA decay in ART-naïve patients starting dolutegravir plus lamivudine vs triple therapy

F. Lombardi

OP 47

Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort

G. Baldin

 
 
OP 48

Prevalence and incidence of multidrug resistance in the ARCA database, 2020 update

F. Incardona

 
 

Coinfections and Hepatitis

OP 19

Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)

N. Coppola

 
 
OP 20

HBeAg levels vary across the different phases of HBV infection, and can be predictive of therapeutic outcome in the setting of immunosuppression-driven HBV reactivation

L. Piermatteo

 
 
OP 21

HCV knowledge and awarness among injecting drug users in the direct acting antivirals era

A. Boschini

 
 
OP 22

A pilot intervention for HCV elimination among MSM in Rome: an update on more than 1200 screened individuals

P. Piselli

 
 
OP 23

Humoral response to mRNA SARS-CoV-2 vaccine in cirrhotic patients without prior exposure to the virus

C. Sorace

 
 
OP 24

Syphilis reinfection in people living with HIV (PLWH): a monocentric retrospective study

G. Tiecco

Comorbidities / Miscellaneous

OP 7

MARAND-X: clinical trial on the use of less neurotoxic antiretrovirals in HAND

A. Lazzaro

 
 
OP 8

Management of diabetes mellitus in people living with HIV and diabetes: a single-center experience

C. Resnati

 
 
OP 9

The interplay between resilience and health related quality of Life in PLWH during the COVID era: a comparison of a geriatric cohort with a cohort of PLWH younger than 65 years

G. Guaraldi

OP 10

Efficacy and Tolerability of Doravirine + Raltegravir combination regimen as therapy of switch in ART experienced PLWHIV: the DOR-INI experience

M. Poliseno

 
 
OP 11

Trends of polypharmacy and 2DR antiretroviral use: a 15-year observational matched-cohort study

S. Cantergiani

OP 12

Rapid, drug-resistance-driven, start of antiretroviral therapy: an open-label, prospective, proof-of-concept, clinical study (TWODAY Study)

N. Gianotti

Epidemiology / Social Sciences I

OP 31

SARS-CoV-2 evolutionary dynamics in the first phase of the epidemic in Italy

A. Lai

 
 
OP 32

Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene

M.C. Bellocchi

 
 
OP 33

Impact of COVID pandemic and anti-SARS-CoV-2 immunization on vaccination against sexually transmitted infections

R. Rossotti

OP 34

Influenza vaccine: knowledge and beliefs among adherent PLWH during the first seasonal campaign of the COVID-19 era

S. Storti

OP 35

Results of a SARS-CoV-2 worker screening in the Marche Nord companies to prevent virus infection in the workplace

A. Casabianca

 
 
OP 36

A mixed method of follow-up with total patient care provided continuum with saving of hospital checks during the COVID-19 pandemic

P. Fusco

Epidemiology / Social Sciences II

OP 37

HIV-related internalized stigma and patient health engagement (PHE) model in an Italian cohort of people living with HIV

V. Massaroni

OP 38

Talking about stigma and Hiv prevention, the artists' contribution

G. Dessì

OP 38

Talking about stigma and Hiv prevention, the artists' contribution

 
 
OP 39

A visual scale to evaluate the quality of life in PLWHA. Fourth-90, utopia or reality?

F. Paciosi

 
 
OP 40

Health-related quality of life (HRQoL) from HIV patients' perspective: comparison of patients-reported outcome (PRO) measures among people living with HIV (PLWH) and other chronic clinical conditions

C. Seguiti

OP 41

Using technology to support vulnerable PLWHIV at the time of coronavirus

S. Patrucco

 
 
OP 42

Impact of SARS-CoV-2 pandemic on quality of life in people with HIV

M. Fois

 
 

Epidemiology / Social Sciences III

OP 73

Pre-Exposure Prophylaxis (PrEP) though the SARS-CoV-2 pandemic period: the experience of the dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence

E. Salomoni

 
 
OP 74

PreP experience at Milano Checkpoint: promoting health and well-being through the integration of complementary skills

A. Bianchi

 
 
OP 75

Rapid tests in the pandemic: the "continuum of care" of Villa Maraini during the Covid-19 emergency

T. Di Giovanni

OP 76

Covid-19 in HIV/AIDS out-of-hospital facilities in Lombardy

L.A. Rancilio

 
 
OP 77

The COVID-19 pandemic impact on retention in care and viral suppression at the Infectious Diseases Unit of S. M. Annunziata Hospital, Florence: comparing 2019 and 2020 data

C. Costa

OP 78

Reaching 90-90-90 in the municipality of Kilamba Kiaxi, Luanda, Angola. The experience of PIPSA project

T. Baldoni

 
 

HIV & Covid I

OP 13

UV irradiation and SARS‐CoV‐2: a focus on UVA/UVB/UVC -inactivation on viral replication

S. Strizzi

 
 
OP 14

Determinants and characteristics of progressor and non progressor SARS COV-2 infected patients

P. Zuccalà

 
 
OP 15

Metabolic associated fatty liver disease is highly prevalent in the post-acute COVID syndrome

J. Milic

OP 16

Assessment of well-being, resilience and intrinsic capacity in patients with post-acute COVID-19 syndrome

T. Marchio

OP 17

Achieving virological control in pan-resistant HIV-1 infection

D. Canetti

OP 18

Resilience and frailty in people living with HIV during the COVID era: two complementary constructs associated with health-related quality of life

G. Guaraldi

HIV & Covid II

OP 49

Real life use of the anti-SARS CoV-2 monoclonal antibodies in the early phase of infection: planning, enrollment, administration and monitoring

C. Del Borgo

OP 50

Learning by doing: effects of monoclonal antibody treatment on the outcome of ambulatory patients with COVID-19

C. Leanza

 
 
OP 51

Efficacy, safety and virological clearance in course of treatment with anti-SARS-CoV-2 monoclonal antibodies in patients diagnosed with mild-moderate COVID-19

C. Falcinella

OP 52

Ex vivo efficacy of currently licensed anti-SARS-CoV-2 monoclonal antibodies

F. Dragoni

OP 53

Real-life use of remdesivir-containing regimens in Coronavirus Disease-2019: a retrospective case-control study

F. Cogliati Dezza

OP 54

SARS-CoV-2 infection Among Persons living with HIV

S.R. Bruno

 
 

Immunopathogenesis I

OP 25

Decreased neutralization of the B.1.525 (Nigerian) SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals

I. Vicenti

OP 26

Severity of COVID-19 patients predicted by serum sphingolipids signature

E. Torretta

 
 
OP 27

Expansion of myeloid derived suppressor cells contribute to platelet activation by L-Arginine deprivation during SARS-CoV-2 infection

A. Sacchi

 
 
OP 28

Cysteamine is an approved drug with antiviral and immunomodulatory properties promising for COVID-19 treatment

T. Alonzi

 
 
OP 29

High CD169 monocyte/lymphocyte ratio reflects the immuno-phenotyping disruption and predicts oxygen need in COVID-19 patients

M. Fanelli

OP 30

Effect of SARS-CoV-2 sequences on immune response in A549-ACE2 lung cells

G. Cappelletti

 
 

Immunopathogenesis II

OP 55

Increased rates of indeterminate QuantiFERON-TB Gold Plus assay in severe COVID-19 patients reflect an impaired interferon-gamma secretion and correlate with the profound reduction of T-lymphocyte subsets in peripheral blood

A. Imeneo

 
 
OP 56

Role of serum E-selectin as a biomarker of infection severity in Coronavirus Disease-19

E. Rando

 
 
OP 57

Effects of viremia and CD4 recovery on the gut “microbiome-immunity” axis in naïve HIV-1 patients undergoing ART therapy

G. Nannini

 
 
OP 58

Cytokine profile of COVID-19 patients with and without active tuberculosis

S. Villa

OP 59

Role of Tocilizumab in down regulating the concentration of sCD163 in a cohort of SARS-COV 2 infected patients with varying severity

A. Carraro

 
 
OP 60

Clinical and immunological characterization of SARS-CoV-2 infection in children

M. Stracuzzi

 
 

Immunopathogenesis III

OP 61

Binding and neutralizing antibodies to interferon (IFN) α/β and defective IFN transcriptional profile in COVID-19 patients

F. Frasca

OP 62

Plasma cytokine landscape reveals the importance of different molecular pathways in predicting COVID-19 severity and survival

L. Gibellini

OP 63

Pregnant women develop a specific immunological long-lived memory against SARS-CoV-2

C. Fenizia

 
 
OP 64

Role of Type-I and -II interferons in SARS-CoV-2 infection: convergent effect, different mechanisms

F. Limanaqi

 
 
OP 65

Persistence of humoral immune response after one year from COVID-19 diagnosis: evidence from a monocentric study

P. Saltini

 
 
OP 66

Immunogenicity and safety of two doses of BNT162b2 vaccine in very elderly subjects

M. Beltrami

 
 

Social Sciences / Miscellaneous

OP 67

Patient outreach strategy to enhance retention to care of HIV-positive adolescent and youths: experience from HIV high burden setting

F. Di Gennaro

 
 
OP 68

Knowledge of HIV and STIs: which are the most vulnerable populations? Results from a web-based survey in Italy

A. Colpani

 
 
OP 69

HIV and Adolescents. Evaluation of an HIV and STI prevention project for high school students

D. Zagato

OP 70

SARS-CoV-2 variants surveillace highlights local emergence of different genotypes

C. Veneziano

OP 71

Access to HIV testing before and after SARS-CoV-2 pandemic in Milan: comparison between a health-care setting and a community setting

L. Biasioli

 
 
OP 72

Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort

M. Ranzenigo

Virology

OP 79

Molecular evidence of HIV-1 transmission in a criminal case in Italy

L. Fabeni

 
 
OP 80

Assessment of specific immunological response after administration of anti-meningococcal quadrivalent conjugate vaccine MENVEO® in a population with vertically-transmitted HIV infection

E. Longoni

 
 
OP 81

Regulation of m6A methylation as new therapeutic option against COVID-19

C. Zannella

OP 82

Characterization of humoral and cellular immune response after SARS-CoV-2 mRNA vaccine in HIV-1 infected patients

L. Santinelli

OP 83

Safety and tolerability of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine in a diverse cohort of people with HIV (PWH)

L. Ferrari

 
 
OP 84

Differences in response to mRNA BNT162b2 vaccine among a cohort of Health Care Workers (HCWs): insights into the potential of a booster dose

M. Allegrini

×

Ascolta il commento

Chiudi